Literature DB >> 2291667

In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.

E L Fasola1, J A Moody, D N Gerding, L R Peterson.   

Abstract

The in vitro activity of LY 264826, a new glycopeptide antibiotic, was compared with that of vancomycin against 100 strains each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. LY 264826 was more active, by weight, than vancomycin against the isolates tested. The human serum protein binding of LY 264826 was 15.3% (range, 9.8 to 21.8%).

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2291667      PMCID： PMC171979          DOI： 10.1128/AAC.34.10.2007

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibiotics.

Authors:  L R Peterson; W H Hall; H H Zinneman; D N Gerding
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

2.  Assay of 27 antimicrobials using a microbiological method.

Authors:  L R Peterson; D N Gerding; C E Fasching; C Costas-Martinez
Journal:  Minn Med       Date:  1983-05
  2 in total
  1 in total

1.  In vitro activity of the new glycopeptide LY264826 versus vancomycin against clinical isolates of enterococci.

Authors:  C Watanakunakorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.